Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. During the past couple of decades, investigators have discovered two different types of cannabinoid receptors in the brain, spinal cord, and peripheral tissues, including immune tissues.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. More than 8 percent of those surveyed also reported already using cannabinoids, with 54 percent noting a beneficial clinical effect.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. The study, led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics , found anxiety was among the top three reasons for a medicinal cannabis prescription. Very few studies have also been done examining cannabis for the treatment of sleep disorders.

Medicine 52

Medicine Clinical Trials Sleep Data 52

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS).

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

Cannabis Law Report

NOVEMBER 22, 2021

Emyria was listed on the ASX last year, just before Australia was plunged into the global COVID-19 pandemic, and has been progressing with trials of a synthetic cannabinoid targeting mental health which it hopes to have registered domestically and in the American market. Read more [link].

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. Most recently the FDA awarded MMJ International Holdings ?Orphan 561-627-9455.

DEA 66

DEA Clinical Trials THC Research and Development 66

Otherside Farms

JANUARY 25, 2019

Scientists hope to perform human trials in the near future. Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. The brief survey can be taken here.

THC 59

THC Clinical Trials Data Consumption 59

CannaMD

OCTOBER 29, 2020

On the contrary, after analyzing cross-sectional data from two population-based surveys including over 50,000 respondents, the American Journal of Epidemiology reports: The proportion of obese participants decreased with the frequency of cannabis use. Cannabis: 2. What’s scarier than a Halloween mask? Cannabis: 3. Shaking with fear!

Research and Development 92

Research and Development Blood Pressure Data Clinical Trials 92

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Does the Data Justify the Conclusions? Investigating the Impact of MMJ Cards. Daily Cannabis Use as a Disqualifier.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

The Cannigma

JUNE 23, 2022

While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. Common cannabinoids in cannabis. What does CBGA do?

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. His deep expertise across clinical development and related functions makes him a tremendous and timely addition to our team,” said Anthony Johnson, M.D., CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Healer

MARCH 26, 2021

Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. THC is the main psychoactive compound in marijuana, while CBD is a non-intoxicating cannabinoid found in the cannabis plant.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.

Research and Development 108

Research and Development Data THC Clinical Trials 108

The Joint Blog

JANUARY 23, 2020

Marijuana may be use “in the treatment of a range of psychiatric disorders”, according to a new study published in the journal BMC Psychiatry. The study is titled “Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.”

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. We could potentially develop north of 11,000 drugs that are cannabinoid-based. This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98